GEN Exclusives

More »

GEN News Highlights

More »
Dec 17, 2010

Pfizer and DiaGenic Collaborate on Blood-Based Gene-Expression Signatures for Early AD

  • Pfizer and DiaGenic have agreed to an explorative R&D collaboration that aims to identify biomarkers of the early stages of Alzheimer disease (AD) using the latter’s gene-expression technology and its blood samples from ongoing clinical trials.

    The ultimate aim is to identify gene-expression patterns indicative of different stages of disease, from early mild cognitive impairment (MCI) through to full-blown AD. To this end the firms will carry out a joint modular study comparing longitudinal changes in blood-based gene-expression patterns in subjects with stable MCI, progressive MCI (prodromal AD), and full AD.

    The agreement gives Pfizer a nonexclusive, worldwide license to use DiaGenic’s MCI test and AD tests for its R&D programs. “MCI progression biomarkers will be very useful in drug discovery, in clinical trials as surrogate markers of treatment efficacy, as well as being very valuable as diagnostic tests in clinical practice,” suggests DiaGenic CEO Erik Christensen, M.D.

    DiaGenic specializes in the development of peripheral blood-based diagnostic tests based on gene-expression signatures for the early detection of diseases. The firm’s first two products, ADtect® for the early detection of AD and BCtect® for the early detection of breast cancer, have received regulatory approval for Europe and are being launched in selected markets.

    The firm’s pipeline is focused on its gene expression-based MCItect™ test for identifying patients with MCI that will convert to AD and its PDtect® test for the early diagnosis of Parkinson disease.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »